Allarity considers partnerships for the potential launch of cancer drug

Within 12 months, Allarity Therapeutics will hopefully know whether cancer drug dovitinib has been approved by the FDA in the US. Subsequent marketing efforts might happen with a partner, says CEO Steve Carchedi.

Steve Carchedi, CEO at Allarity Therapeutics | Photo: Allarity Therapeutics / PR

After several years of preparation, one of Allarity Therapeutics’ biggest days came along shortly before Christmas, when the firm could submit for approval its drug, dovitinib, against kidney cancer to the US Food and Drug Administration (FDA).

”It was a historic milestone,” CEO at Allarity Therapeutics Steve Carchedi tells MedWatch today.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs